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Abstract
Bladder cancer is among the top ten most common cancer types in the world, with approximately 550,000 new cases annually. 
The highest burden of bladder cancer is currently falling on most developed communities across the globe. But with an antici-
pated shift in world demographics with growing and aging populations mainly on the African continent, and important shifts 
in exposure to different risk factors across the world, this is likely to change over the next decades. In this review, we provide 
an overview of the current incidence, mortality, prevalence, survival, risk factors and costs of bladder cancer worldwide.
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Cancer across the globe
Each year, more than 18 million new cases of cancer are 
diagnosed worldwide. Globally, one in every five people will 
develop the disease before the age of 75 years, but this varies 
from 1 in 10 in South-Central Asia and Middle-Africa to 1 
in 2.5 in Australia and New Zealand. Currently, there are 
approximately 44 million cancer patients alive who were 
diagnosed less than 5 years ago. Almost 10 million people 
die from cancer annually [1].
Approximately 3.0% of all new cancer diagnoses and 
2.1% of all cancer deaths are due to urinary bladder cancer 
(UBC) [1]. In this overview we will describe the burden of 
UBC in the world regarding incidence, survival, mortality, 
prevalence and risk factors. Moreover, we reflect on (antici-
pated) changes in demography and economic situation in 
different parts of the world and the impact these changes 
may have on the burden of UBC [2].
Assessing the burden of UBC is complicated 
by definition differences
Assessing the burden of UBC worldwide is reliant upon the 
availability of cancer registry data [3]. The International 
Association of Cancer Registries (IACR) has made major 
steps towards increasing the proportion of the world popu-
lation covered by national or regional cancer registries. To 
date, national cancer registries are mainly situated in Euro-
pean countries and Australia. In other, more developed coun-
tries, often regional cancer registries are present whereas in 
less developed countries there is a lack of national and/or 
regional population-based cancer registries [4, 5].
Several international rules and guidelines have been 
developed to enhance comparability across cancer registries. 
In general, cancer registries adhere to the International Clas-
sification of Diseases for Oncology (ICD-O) and other sys-
tems such as the TNM system and grading systems.
Despite the use of uniform coding systems like the ICD-O 
and TNM, UBC has some specific features that should be 
kept in mind when comparing data from different areas of 
the world or different time periods. Some cancer registries 
include non-invasive (Tis and Ta) UBC while other registries 
only include invasive (≥ T1) cancers. T1 tumors are invasive, 
but not muscle-invasive. Their clinical course and treatment 
are more like Ta tumors, which is reason to group Ta and T1 
tumors as non-muscle-invasive tumors. Because Ta tumors 
make up about 50% of all new UBC diagnoses, inclusion 
or exclusion of these Ta tumors has an enormous impact. 
While non-muscle-invasive tumors are usually treated 
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locally, treatment of muscle-invasive tumors often involves 
a radical cystectomy or alternatively, (chemo)radiation and 
have much worse survival rates. Naturally, such registration 
differences may have a huge effect on the comparison of 
incidence, prevalence and survival estimates.
In addition to registration differences, the term ‘invasive’ 
may be confusing in reports or publications if it is not well-
defined because it may both be used to describe cancers that 
invade the lamina propria (≥ T1, as defined by the TNM 
system), or tumors that invade the bladder muscle (≥ T2, as 
usually referred to by clinicians).
In this paper, most data are derived from GLOBOCAN 
2018 which includes non-invasive UBC, unless stated oth-
erwise. GLOBOCAN (The Global Cancer Observatory by 
the International Agency for Research on Cancer [IARC]) 
is based on several key IACR projects, including Cancer 
Incidence in Five Continents (CI5), and offers an interactive 
web-based platform presenting global cancer statistics. It 
includes a module that provides data visualization tools that 
present current national estimates of the incidence, mortality 
and prevalence of 36 cancer types in 185 countries by sex 
and age group [6].
UBC occurrence is about threefold higher 
in Europe and North America
Although usually not perceived as such by the general popu-
lation, UBC is among the more commonly occurring can-
cers. It ranks tenth in worldwide absolute incidence: sixth in 
men and seventeenth in women [6]. Approximately 550,000 
new UBCs (almost 425,000 in males and over 125,000 in 
females) were diagnosed worldwide in 2018 [6]. The world-
wide Age Standardized Incidence Rate per year (ASR) is 
9.6 per 100,000 for males and 2.4 per 100,000 for females. 
Figure 1 shows the worldwide ASRs for UBC in both sexes.
The incidence varies significantly between geographi-
cal regions, with the highest rates (ASR in males ≈ 20 per 
100,000 per year and ASR in females ≈ 4.5 per 100,000 per 
year) observed in Europe and North America, but also in 
Syrian, Israeli, Egyptian and Turkish males. About threefold 
lower rates are seen in South-East Asia, except for Japan, 
and in Latin America and Northern Africa in both sexes [4]. 
The lowest rates are observed in Sub-Saharan Africa, Mex-
ico and some Middle Eastern and Central Asian countries.
Worldwide differences in (historical) exposure to risk 
factors like cigarette smoking, chemical carcinogens 
in certain occupations and arsenic in drinking water or 
endemic chronic urinary infections caused by Schistosoma 
haematobium are largely responsible for the observed 
variability in occurrence, although a small part of the 
geographical differences may also be attributable to dif-
ferences in access to care and availability of diagnostic 
procedures such as enhanced cystoscopy (e.g. narrow 
band imaging or blue light cystoscopy) and computed 
tomography between more and less developed countries 
[7]. Cigarette smoking is by far the number one risk fac-
tor, accounting for up to 50% of all UBC diagnoses, espe-
cially urothelial cell cancer (UCC) [8]. Schistosomiasis 
is mainly associated with the development of squamous 
cell carcinoma (SCC). In regions where this infection is 
or was endemic, specifically Egypt, SCC was for years 
the dominant histopathological type of UBC. However, 
changes occurred over the past decades in these regions 
with increasing proportions of UC, while SCC decreased 
from 78% in 1980 to 27% in 2005 [9]. This is probably 
caused by public health interventions and the construction 
of the Aswan Higher Dam in the Nile Delta in the 1960s. 
This led to a replacement of S. haematobium with S. man-
soni, which is not a risk factor for UBC. The prevalence 
of S. haematobium infection reduced from 74% in 1935 to 
only 4% in 1983 [10]. The extremely high UBC incidence 
(ASR for both sexes > 20 per 100,000) in Lebanon and 
Greece may still reflect exposure to S. haematobium, but is 
expected to decrease due to efforts by the WHO on preven-
tive treatment for schistosomiasis worldwide, especially 
in school-aged children, negating the long-term effects of 
the infection [11].
About 1 in 100 men and 1 in 400 women 
will be diagnosed with UBC sometime in life 
worldwide
Worldwide, the lifetime risk of getting UBC is 1.1% in men, 
and 0.27% in women [6]. The lifetime risk is considerably 
higher in most developed countries, such as the US (life-
time risk in men and women of 3.9% and 1.2%, respectively) 
[12]. Figure 2 shows that the lifetime risk among men and 
women in the US slightly increases from birth until the age 
of 50 years. Only after that, the risk to be diagnosed in the 
remaining life years starts to decline [12]. The risk of devel-
oping UBC in the next 10 years is also presented in Fig. 2 
for men and women of different ages. This risk is highest in 
80-year olds in both males and females.
It should be noted that the lifetime risks are derived from 
current incidence rates of UBC, reflecting UBC predomi-
nantly diagnosed among the elderly, and their past exposure 
to risk factors. If the prevalence of these risk factors has 
changed over time, the actual lifetime risks of the younger 
cohorts will deviate from the risks reported here.
In Table 1 the risk of developing UBC from and until a 
certain age is presented for males and females in the U.S. 
From this table, it becomes clear that the majority of patients 
are diagnosed with UBC at 60 years and older.
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UBC mortality is less variable 
around the globe
Worldwide approximately 200,000 patients died from UBC 
in 2018 [6]. The global ASR for mortality among males is 
3.2 per 100,000 per year versus 0.9 per 100,000 per year 
among females. The variability in UBC mortality around 
the world is not as large as that in UBC incidence. The ASR 
(per 100,000 person-years) among males varies between 4.3 
in countries with a very high Human Development Index 
(HDI) and 2.0 in countries with a low HDI. For females, the 
ASRs per 100,000 person-years vary between 0.33 and 1.1. 
Figure 3 shows the ASRs for mortality for the world. The 
smaller variability is partly because there are less definition 
differences with respect to ≥ T2 cancers which are responsi-
ble for most of UBC mortality and are more often adequately 
Fig. 1  Urinary bladder cancer incidence in 2018 in the world, by sex
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registered as cause of death. Nevertheless, accuracy of 
causes of death registries may vary substantially [13].
Five‑year relative survival for UBC 
is around 70% in Europe
Accurate population-based survival data are scarce, espe-
cially for less developed areas. From the EUROCARE-5 
study, relative survival estimates for UBC patients in 
Europe are available and shown in Fig. 4. In Europe, the 
5-year age-standardized relative survival rate of all UBC 
was approximately 70%, ranging from on average 60–80% 
between individual countries [14]. This enormous variation 
is probably partially explained by differences in proportions 
of non-invasive tumors. Although these data refer to patients 
diagnosed between 2000–2007, the study shows no to only 
minor improvement in survival rates over the years, which is 
corroborated in more recent data from SEER and the NCR.
In most countries, survival rates for women were slightly 
lower than for men. This cannot be completely explained by 
a diagnostic delay in women because stage-adjusted survival 
figures show the same difference [15]. The underlying mech-
anisms are multifactorial, probably including the thinner 
bladder wall in women and hormonal differences between 
genders. Recent studies from Norway and the Netherlands 
show that the survival difference between men and women 
only exist in the first 2 years of follow-up [16, 17].
It is likely that survival rates vary more between coun-
tries with different HDI levels, given less accessibility to 
optimal diagnostics and treatments and divergent competing 
risks of other causes of death. Because of the latter point, 
UBC-specific survival (or alternatively, relative survival) is 
preferable to overall survival to compare countries.
1.65 million people live with UBC worldwide
Prevalence, which is the number of patients alive with UBC 
at a specific point in time is a function of incidence and 
‘duration of the disease’. It can be calculated by preva-
lence = incidence × duration. Duration is, of course, related 
to survival but it is also related to how long a patient with a 
history of UBC is considered to be a UBC patient. For that 
reason, the so-called ‘partial prevalence’ refers to the num-
ber of patients still alive within a defined period following 
diagnosis (usually 5 or 10 years).
The overall global five-year prevalence is estimated at 
1,650,000 (approximately 1,300,000 males and 350,000 
females) in 2018 [6]. In most European and North-American 
countries the 5-year prevalence for men and women is over 
50 per 100,000 and 10 per 100,000 persons, respectively 
Fig. 2  Risk of developing 
urinary bladder cancer for males 
(a) and females (b) in the US. 
Based on data from the Surveil-
lance, Epidemiology, and End 
Results Program (SEER), US, 
2014–2016, all races, males and 
females [12]. Examples of inter-
pretation: a 50-year old man 
has an average risk of 0.28% 
to be diagnosed with bladder 
cancer before his 60th birthday. 
A 60-year old woman has an 
average risk of 1.15% to be 
diagnosed with bladder cancer 
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(Fig. 5). Probably because of a lower incidence and worse 
survival, the prevalence is up to tenfold lower in countries 
such as Mexico, India, Mongolia and sub-Saharan African 
countries.
Population growth and aging will increase 
the number of diagnoses, not the risk of UBC
According to the United Nations, the world population is 
expected to increase from the current 7.6 billion to 8.5 bil-
lion people in 2030 and passing 9.7 billion in 2050; for a 
large part caused by an expected doubling of the African 
population between now and 2050 [18].
Currently, people > 60 years old represent approximately 
13% of the world population, varying from 25% in Europe 
to 5% in Africa. Half of the increase in world population 
will be reflected in a rise in the population aged > 60 years, 
rising from 960 million to 1.4 billion by 2030 and 2.1 billion 
by 2050 [18].
These demographic changes will have an enormous 
impact on UBC occurrence (as well as on most other 
late-onset diseases), and therefore also on prevalence and 
mortality. This will lead to an increasing burden on clinical 
care and society as a whole. It is good to realize that the risk 
of UBC until a certain age is not affected by such changes.
Besides aging, tobacco smoking 
is the strongest determinant for the burden 
of UBC
The population attributable risk (PAR) of tobacco smok-
ing for UBC has been estimated around 50% [19]. Hence, 
alterations in tobacco smoking prevalence will have consid-
erable impact on incidence of UBC, although with a delay 
of several decades.
As of 2015, it seems like the tobacco epidemic is showing 
a decline in most countries in the world.
Figure 6 shows that across medium, high and very high 
HDI countries there is a decreasing trend in tobacco smok-
ing in both men and women. In the low HDI countries 
however, where the proportions of tobacco smokers are 
still much lower than in other HDI groups, it shows a small 
rise of tobacco use among men only. The rise in tobacco 
prevalence is mostly found in Africa (and partly the Middle 
Table 1  Risks of developing 
urinary bladder cancer among 
US males and females (SEER 
data)
This table shows the risk in % from a certain age (first column) until a certain age (top row). The high-
lighted cells contain the risk of developing bladder cancer in the next 10 years (also shown in the solid bars 
in Fig. 2). The last column contains the risks of cancer in the remaining lifetime from a certain age onwards 
(also shown in the dashed bars in Fig. 2)
Age until/
age from
10 20 30 40 50 60 70 80 90 Lifetime risk
Males
 0 0.00 0.00 0.01 0.02 0.09 0.35 1.06 2.35 3.53 3.86
 10 0.00 0.01 0.02 0.09 0.35 1.07 2.38 3.57 3.90
 20 0.00 0.02 0.09 0.35 1.08 2.38 3.58 3.92
 30 0.02 0.08 0.35 1.09 2.41 3.62 3.96
 40 0.07 0.34 1.09 2.43 3.67 4.01
 50 0.28 1.05 2.44 3.71 4.07
 60 0.83 2.32 3.68 4.07




 0 0.00 0.00 0.00 0.01 0.03 0.12 0.33 0.69 1.05 1.18
 10 0.00 0.00 0.01 0.03 0.12 0.33 0.70 1.06 1.19
 20 0.00 0.01 0.03 0.12 0.33 0.70 1.06 1.19
 30 0.01 0.03 0.12 0.33 0.70 1.06 1.19
 40 0.02 0.11 0.32 0.70 1.07 1.20
 50 0.09 0.31 0.69 1.06 1.19
 60 0.23 0.62 1.01 1.15
 70 0.44 0.87 1.02
 80 0.54 0.73
 90 0.38
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Eastern countries), and only in men (Fig. 6). Provided that 
Africa is also the region that accounts for most of the world 
population growth, this trend is likely to have considerable 
impact on incidence.
It should be taken into account that the consequences of 
tobacco use manifest several decades later.
Smoking prevalence in Western Europe started to decline 
from the 1950s among men and from the mid 1970s among 
women [20]. Due to strong anti-smoking policies in the 
highest HDI countries, the decrease in UBC incidence is 
likely to continue, whereas an increasing trend is expected 
in low HDI countries lacking such policies.
Several policy actions in Western countries, such as high 
taxes on tobacco products and banning of tobacco adver-
tising, have led to a considerable decrease of tobacco use. 
For instance, the prevalence of daily smoking among adult 
Fig. 3  Urinary bladder cancer mortality across the world in 2018, by sex
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Australians is only 14.5%, in Norway 13.0% [21]. These 
policies, if implemented in other regions of the world, might 
help to mitigate the impact of the tobacco epidemic else-
where. For instance, it could lower the overall level and 
duration of the tobacco epidemic in Africa and the Middle 
East and speed up the decrease in tobacco use in the Far 
Eastern countries, where such regulations are still sub-opti-
mal despite recent improvements [22]. On the other hand, 
the tobacco industry is marketing its products more aggres-
sively in low and middle income countries now that the 
fight against smoking is more prominent in the high income 
countries.
Policy‑level actions to cope with the global 
burden of UBC
This overview illustrates that the global burden of UBC is 
high, with an estimated 550,000 new cases of UBC every 
year. To date the burden is still highest in developed com-
munities but with increasing exposure to risk factors, such 
as smoking, and a strongly increasing life expectancy, this 
burden is expected to increase in the developing world in 
the near future.
A major part of the future increase in UBC burden will 
be inevitably attributable to the growing and aging world 
population. The single major actionable contributor is still 
tobacco use, and part of the UBC burden can be averted with 
policy measures to prevent and stop tobacco use. Urgent 
action on cancer control should be taken with a focus on pri-
mary prevention of smoking in developing areas, especially 
in the Middle East and Africa. Smoking cessation should 
also be stimulated through policy measures, because it 
impacts overall life expectancy and quality of life and poten-
tially also impacts the risk of recurrence and disease pro-
gression in UBC patients [23–25]. Smoking cessation also 
impacts the social surrounding of the ex-smoker, denormal-
izing smoking in society for other potential smokers [26].
The WHO Framework Convention on Tobacco Control 
is actively enforcing policies across the world to do so [27]. 
Policies that have been most successfully implemented so far 
are protection from tobacco smoke, packaging and labeling 
of products and sales to minors. Enforcement of tax and 
price measures on tobacco products is also increasing to 
suppress the demand for tobacco products, although this is 
lagging behind in other continents than Australia, Europe, 
and North America.
It is vital to curb the projected increase in UBC incidence 
because it affects population health and wellbeing, but not in 
the last place to control related health care costs. UBC has 
the highest lifetime treatment costs per patient of all cancers, 
with total costs of 3.6 billion euro per year in the US and 
almost 5 billion euro in Europe [28, 29]. This is due to high 
recurrence rates in the large group of non-muscle-invasive 
UBC patients, and associated intensive surveillance strate-











100 Individual country 
Weighted average of area 
Weighted average of Europe 
Fig. 4  Five-year relative survival of urinary bladder cancer patients 
in European countries by sex. Data from EUROCARE-5 based on 
429,154 cases of bladder cancer (ICD-O-3 topography C67, including 
non-invasive tumors) diagnosed between 2000 and 2007 with follow-
up until 2008 from 86 population-based cancer registries from 29 
European countries [14]. Relative survival rates are age-standardized. 
Error bars represent 95% confidence limits. Survival estimates from 
Scotland and The Netherlands reflect only invasive bladder cancer
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select patients with non-muscle-invasive UBC that will 
benefit from less intensive surveillance schedules will both 
mitigate health care costs of surveillance and burden on the 
individual patient. There have been several studies on the 
value of population-based screening for UBC but formal 
screening programmes have never been adopted [31]. In 
some occupational situations in which workers were exposed 
to bladder cancer carcinogens screening programmes have 
existed or may still exist [32]. In any case, the quantitative 
effect on UBC occurrence of screening for UBC seems very 
small. Another projected source of high expense is the use of 
expensive therapies in the final stages of disease (and soon 
in the neoadjuvant setting) with the recent introduction and 
future expanding use of checkpoint inhibitors. Research is 
necessary to identify patients most likely to benefit from 
these interventions. To make sufficient progress, funding 
for research focusing on UBC has to become more in line 
with the incidence and financial burden respective to other 
Fig. 5  Five-year urinary bladder cancer prevalence rates in 2018 in the World, by sex
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research priorities after years of disproportionate allocation 
[33].
Conclusions
In conclusion, two demographic trends are largely respon-
sible for increasing UBC occurrence worldwide: overall 
population growth and aging of populations (mostly on the 
African continent). Although a decreasing trend in tobacco 
use is observed in many areas of the world, this will only 
partly offset the increasing occurrence caused by demo-
graphic trends.
With increasing levels of development in traditionally 
lesser developed areas, better health care facilities will 
become available, which is expected to increase survival and 
subsequently prevalence. Efforts to reduce the overall world-
wide burden of UBC include proceeding and scaling-up pol-
icies to decrease tobacco smoking, developing minimally 
intensive follow-up programs for patients with NMIBC, 
making high-quality facilities for diagnosis and manage-
ment accessible in less-developed countries and developing 
ways to accurately identify patients who will benefit from 
expensive therapies.
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